Product Performance and Advisories
Neuromodulation
Product performance overview introduction
Medtronic uses a prospective, long-term multi-center registry to monitor the performance of certain neuromodulation products at selected centers. This 2023 product performance report provides data on the devices followed in the registry. Medtronic also incorporates the findings of returned product analysis (RPA) for devices followed in the registry that are returned to Medtronic.
Depending upon geography, this report may contain information outside approved labeling for commercially available devices from Medtronic. It is recognized that healthcare providers prescribe approved therapies to meet specific patient needs; however, Medtronic only directs the use of its products according to geography-specific, approved labeling.
Deep brain stimulation tables and graphs in this report generated based on data collected between July 2009 and the report cut-off date of October 31, 2023. Sixty-four centers, in North America, Europe, South America, Asia, and Australia have enrolled and contributed patients to the deep brain stimulation systems section of this report.
Sacral neuromodulation tables and graphs in this report were generated based on data collected between April 2010 and the report cut-off date of October 31, 2023. Twenty-four centers in North America, South America and Europe enrolled and contributed patients to the sacral neuromodulation section of the report.
Spinal cord stimulation tables and graphs in this report were generated based on data collected between June 2004 and the report cut-off date of October 31, 2023. Eighty-five centers in North America, Europe and South America, have enrolled and contributed patient data to the spinal cord stimulation section of the report.
Targeted drug delivery tables and graphs were generated based on data collected between August 2003 and the report cut-off date of October 31, 2023. Seventy-six centers spanning 13 countries/territories in North America, Europe and South America enrolled and contributed patient data to the targeted drug delivery systems section of the report.
